The market is selling machines. The procedure still depends on the physician.
Radiofrequency ablation remains the strongest overall foundation for a thyroid-ablation program. Microwave ablation is the principal established alternative. Within MWA, Canyon now emerges as the clinical-evidence leader, while ECO, Baird and Vison lead on different commercial dimensions. Ethanol remains essential for cystic disease. Nanosecond pulsed-field ablation is the most important emerging nonthermal technology. None of these conclusions outrank ultrasound expertise.
Best core modality
Radiofrequency ablation has the deepest thyroid-specific evidence, guidelines and training infrastructure.
Best device ecosystem
STARMED VIVA combines mature thyroid electrodes, training reach and an explicit U.S. benign-nodule indication.
Best RFA alternative
RF Medical THYBLATE/Mygen is the strongest non-STARMED option when mentorship, service or economics are better.
Technology to watch
nPulse Vybrance is scientifically differentiated but remains early in thyroid evidence and commercial adoption.
2026 rankings at a glance
These rankings are an editorial assessment of clinical evidence, thyroid specificity, regulatory position, adoption, training infrastructure, service and international footprint. They are not audited worldwide sales rankings.
Modalities for a new thyroid-ablation program
Manufacturer and platform ranking
Who actually leads thyroid MWA?
The deeper review changes the answer from a single winner to a leadership map. “Leader” depends on whether the question is clinical evidence, commercial scale, thyroid-specific commercialization or regional distribution.
| Leadership dimension | Platform | Why | Important limitation |
|---|---|---|---|
| Clinical-evidence leader | Canyon Medical | The KY-2000 has the strongest device-specific thyroid MWA record identified, including a five-center randomized two-year comparison with STARMED RFA. | The trial received Canyon support, used operators with more than 10 years of thermal-ablation experience and was not powered to prove equal safety. |
| Overall Chinese commercial-scale leader | ECO Medical | Ranked first in overall 2022 Chinese MWA revenue in the Frost & Sullivan data cited in Baird’s public filing. | The dataset was commissioned for a company filing, is China-specific and does not establish current worldwide leadership. |
| China thyroid-commercialization leader | Baird Medical | Ranked first in the cited Chinese thyroid-nodule and breast-lump MWA segment by revenue and needle volume. | Independent device-specific comparative thyroid evidence remains thinner than Canyon’s and ECO’s. |
| Major overlooked scale player | Vison Medical | Ranked second in overall Chinese MWA revenue in the cited 2022 data; the MTC-3C appears in contemporary large-nodule thyroid studies. | Its thyroid-specific international training and evidence ecosystem is less visible. |
| European specialist platform | Biomedical / Terumo TATO | Dedicated fine thyroid antennas, European clinical adoption and established EMEA distribution. | Smaller global thyroid evidence and installed-base visibility than the principal Chinese platforms. |
What the ranking measures
What determines a successful thyroid ablation—in the correct order
Device discussions frequently reverse the clinical hierarchy. The manufacturer belongs near the bottom, not the top.
Ultrasound is the primary safety system
- Maps the recurrent laryngeal nerve danger zone, trachea, esophagus, carotid artery and jugular vein.
- Determines whether the applicator remains visible from skin entry to active tip.
- Guides hydrodissection and confirms that protective fluid planes remain intact.
- Shows marginal vessels, untreated viable tissue and the relationship between tumor and capsule.
- Separates curative-intent treatment from incomplete debulking.
The best device in inexperienced hands is not the best treatment.
The best modality depends on the disease
No single machine is ideal for cystic nodules, benign solid nodules, autonomous disease, primary cancer, recurrent neck disease, massive goiter and distant metastases. A comprehensive center must be able to recommend a treatment it does not personally provide.
Educational modality guide
Select a clinical category to see the report’s high-level treatment logic. This is not patient-specific medical advice.
| Disease or lesion | Patient-centered preferred approach | Key caveat |
|---|---|---|
| Pure or predominantly cystic benign nodule | AspirationEthanol | Thermal ablation may be added for a persistent vascular solid component. |
| Small or medium benign solid nodule | RFA | Precision and complete marginal treatment depend on ultrasound skill. |
| Large solid nodule | RFAMWA | Anatomy, vascularity, operator experience and likelihood of staged treatment matter. |
| Highly vascular large nodule | MWAStaged RFA | Evidence does not justify a universal MWA-first rule. |
| Autonomously functioning nodule | RFARAI / surgery comparison | Biochemical cure is less predictable when large-volume tissue remains untreated. |
| Selected low-risk papillary microcarcinoma | Active surveillanceSurgeryExpert-center ablation | Complete staging and long-term surveillance are mandatory. |
| Limited thyroid-bed recurrence or selected metastatic node | SurgerySmall-tip RFASelected ethanol | A benign-nodule skill set is not sufficient for oncologic ablation. |
| Massive multinodular or toxic goiter | SurgeryRadioiodineStaged ablation / embolization | Diffuse disease requires a multidisciplinary rather than device-centered plan. |
| Bone, lung, liver or adrenal metastasis | Organ-specific interventional oncology | Device choice follows the metastatic organ, disease burden and systemic strategy. |
How the modalities compare
1. Radiofrequency ablation
The strongest overall foundation for a thyroid-ablation program.
RFA has the broadest thyroid-specific literature, extensive international guidance, fine thyroid electrodes and the largest mature training community. A 2025 systematic review and meta-analysis found RFA and MWA both effective, with a higher pooled 12-month volume-reduction rate for RFA and an apparent advantage among less-experienced investigators.4
Best suited for
- Small and medium benign solid nodules
- Irregular geometry
- Lesions near vulnerable anatomy
- Selected autonomous nodules
- Selected recurrent cervical disease at expert centers
Limitations
- Operator-dependent
- May be slower for large nodules
- Requires multiple overlapping ablation units
- Large nodules may require repeat treatment
- Monopolar systems add pads, pump and consumables
2. Microwave ablation
The principal established thermal alternative.
MWA can deliver energy rapidly, create larger treatment zones and operate with less dependence on tissue impedance. Canyon’s KY-2000 was used in a prospective randomized five-center trial in which MWA was noninferior to STARMED RFA for two-year volume reduction in predominantly solid benign nodules.16 The study is the strongest head-to-head device evidence identified in this review, but it was supported by Canyon, all operators had more than 10 years of thermal-ablation experience, and the study was underpowered to establish comparable safety. Voice change occurred in 6.6% of the MWA group and 1.3% of the RFA group, a difference that was not statistically conclusive.16 A separate propensity-matched study comparing STARMED RFA with ECO MWA found comparable overall 12-month reduction; ECO MWA required less treatment time and energy, with a higher 12-month reduction in nodules at least 3.5 cm in that cohort.8 These findings support MWA as an established alternative, not a universal first choice.
Potential advantages
- Faster central debulking
- Large solid nodules
- Highly vascular lesions
- Less sensitivity to tissue impedance
Limitations
- Rapid thermal propagation
- May be less forgiving near critical structures
- Variation among antennas and protocols
- Less standardized thyroid training outside major centers
3. Laser thermal ablation
Established precision technology with its deepest base in Europe.
Laser uses fine optical fibers and controlled energy delivery. It has substantial European experience, especially in Italy, and is recognized in European guidance as an image-guided ablation option.2
Strengths
- Fine introducer needles
- Controlled geometry
- Long European clinical history
Limitations
- Multi-fiber placement
- Smaller worldwide training base
- Less adoption in North America and Asia
4. High-intensity focused ultrasound
The only established completely noninvasive option.
HIFU avoids skin puncture, but patient anatomy, target depth, calcification, air and bone can restrict the treatment window. Long procedure times, capital cost and limited availability keep it a specialist rather than core platform.
5. Nanosecond pulsed-field ablation
The most important emerging nonthermal technology.
Pulse Biosciences’ nPulse Vybrance platform delivers nanosecond electrical pulses rather than thermal energy. Early company-reported benign-nodule durability data are encouraging, but large comparative trials, long-term outcomes, reimbursement and broad real-world adoption remain unresolved.1011
Essential companion: Ethanol ablation
Often the correct first intervention for cystic disease.
Ethanol is inexpensive, widely available and recommended for appropriate cystic or predominantly cystic nodules. A center that owns an expensive thermal platform but does not offer ethanol may still provide the wrong treatment to a cystic-nodule patient.2
Selective option: Thyroid artery embolization
Relevant to selected massive, diffuse, hypervascular or toxic disease.
A 2025 systematic review found evidence of volume reduction and symptom improvement but emphasized heterogeneous protocols, limited comparative evidence and potentially serious nontarget risks. Current evidence supports concentration in specialist centers rather than routine replacement of surgery, radioiodine, RFA or MWA.12
Platform profiles and defensible claims
STARMED VIVA
STARMED combines a long association with modern thyroid RFA, dedicated short internally cooled electrodes, adjustable-tip options, extensive training activity and broad representation in the literature.
FDA cleared K252833 in May 2026 with an explicit indication for ultrasound-guided percutaneous ablation of eligible cytologically confirmed benign thyroid nodules in adults.5
RF Medical THYBLATE / Mygen
RF Medical offers a dedicated thyroid line with a familiar monopolar internally cooled workflow and thyroid-specific electrodes. It is a credible modality-equivalent alternative when local mentorship, service, supply or economics are superior.
Its visible international thyroid ecosystem is smaller than STARMED’s, and this review did not identify an equivalent U.S. benign-thyroid-nodule-specific clearance.
Canyon Medical MaxBlate / KY-2000
Canyon is the strongest candidate for the title of thyroid MWA clinical leader. The company’s legacy KY-2000 platform has been used in a randomized five-center comparison with STARMED RFA, a 435-patient benign-nodule cohort, large nodular-goiter series, prospective multicenter research and long-term papillary thyroid microcarcinoma studies.161721
The evidence needs precise framing. The randomized trial was supported by Canyon, involved highly experienced operators and could not prove equal complication safety. Most historical evidence concerns the KY-2000 sold under the Kangyou name. Canyon’s current MaxBlate line uses KY-2000A/KY-2100A generators and fine water-cooled ThyTip antennas; the current product family is a continuation of that corporate and technical lineage, but not every modern antenna configuration has been tested in the same trials.1824
The FDA cleared KY-2000A and KY-2100A in 2024 for general soft-tissue ablation, not a thyroid-specific U.S. indication. Canyon is now a majority-owned Micro-Tech company, which may strengthen international infrastructure, but local service and consumable availability still require country-by-country verification.1925
ECO Medical
ECO is underrepresented in Western discussion. Its systems appear in benign-nodule, Graves’ disease, papillary thyroid cancer and large-nodule research, including a direct propensity-matched comparison with STARMED RFA using an ECO thyroid antenna.826
Commercial market research cited in Baird’s SEC filing ranked ECO first in China’s overall MWA market in 2022. That supports scale, not automatic clinical superiority, and does not establish current worldwide procedure leadership.20
Several important multicenter thyroid-cancer studies used more than one Chinese MWA system, including ECO and Canyon. Their outcomes strengthen MWA as a modality but should not be attributed entirely to either manufacturer.
Baird Medical
Baird has an explicitly thyroid-focused commercial strategy and fine-gauge thyroid antennas. Its U.S. BD-GT system was cleared for general soft-tissue coagulation and ablation—not a thyroid-specific indication—and the 510(k) did not establish device-specific thyroid superiority.9
The Frost & Sullivan data cited in Baird’s public filing placed the company third in China’s overall MWA market in 2022 but first in the thyroid-nodule and breast-lump segment by revenue and needle volume. That is a meaningful commercial distinction, but the research was company-commissioned and independent device-specific comparative thyroid evidence remains less developed than Canyon’s.20
Vison Medical MTC-3C / SurBlate
Vison was the most important manufacturer missing from the earlier ranking. The same commissioned market dataset placed it second in China’s overall MWA market in 2022, ahead of Baird and Canyon.20
Its MTC-3C system was used in a contemporary 205-patient study of benign nodules at least 4 cm, which reported a mean 12-month volume-reduction rate of 82.54% and a technical-efficacy rate of 93.66%. The U.S.-cleared SurBlate system is designed by Vison and manufactured by MIMA-Pro, with a general soft-tissue rather than thyroid-specific indication.2223
Vison’s challenge is not evidence absence but lower international thyroid-brand visibility, a less visible training ecosystem and uncertainty about how directly the MTC-3C literature maps to the current SurBlate commercial configuration.
Elesta EchoLaser
EchoLaser has a long European history and uses fine optical fibers for controlled treatment. Its strengths are precision and mature regional experience; its limits are geographic concentration, multi-fiber workflow and a smaller global training ecosystem.
Biomedical / Terumo TATO
TATO uses a 2.45 GHz uncooled MWA design and offers a dedicated fine thyroid antenna. It benefits from European clinical adoption, Terumo’s EMEA distribution and supportive NICE guidance for percutaneous MWA of symptomatic benign nodules.27
It should be regarded as an important regional thyroid platform rather than a demonstrated worldwide MWA leader.
Pulse Biosciences nPulse Vybrance
nPulse is scientifically differentiated and potentially relevant to fibrosis and collateral thermal injury. Its proper status is high-potential, early evidence—not established replacement for modern RFA or MWA.
Theraclion EchoPulse
EchoPulse provides a needle-free approach. Its limitations—treatment window, anatomy, time, capital cost and limited availability—make it a niche option rather than a first purchase for most centers.
Other credible platforms the ranking should acknowledge
HS AMICA
A long-established European RF/MW platform with 17–18G applicators, U.S. general soft-tissue clearance and published thyroid MWA experience. Its thyroid-specific evidence and training ecosystem are smaller than Canyon’s, ECO’s or TATO’s.28
Olympus CELON
A bipolar RFA platform with documented use for benign thyroid nodules, especially in European practice. It remains technically credible but has a smaller contemporary thyroid-specific global footprint than STARMED or RF Medical.29
MedSphere S-500
A Chinese RFA platform with fine internally cooled thyroid electrodes and published benign-nodule, hydrodissection and thyroid-cancer studies. It is clinically relevant but less visible internationally and has limited public global service data.30
What should a physician starting today actually buy?
The minimum patient-centered setup
Clinical platform
Thyroid-specific RFA plus ethanol ablation. Add MWA only when volume, case mix and expertise support it.
Imaging
High-resolution ultrasound with excellent near-field imaging and complete cervical lymph-node capability.
Safety
Hydrodissection supplies, continuous voice monitoring, hematoma and airway protocols, and surgical backup.
Clinical system
Pathology, endocrinology, surgery, follow-up ultrasound, outcomes tracking and a pathway for patients who should not receive ablation.
Drawbacks to STARMED
No proof of universal brand superiority
Strong modality and ecosystem evidence do not prove that the generator outperforms all RF Medical systems in equally skilled hands.
Proprietary consumable dependence
Electrodes, pads, pump components, service and distributor reliability affect the total cost of ownership.
Setup and workflow
Monopolar RFA typically requires a cooling pump, tubing, grounding pads and careful impedance management.
Large-nodule efficiency
RFA may be slower than MWA for selected large solid lesions and may require staged or repeat treatment.
Specific—not universal—clearance
The U.S. benign-nodule indication does not automatically extend to thyroid cancer, parathyroid or every off-label use.
Vendor-training dependency
A large training ecosystem is valuable, but independent mentorship and society guidance remain necessary.
A physician should purchase the platform used by the expert who will proctor the first cases—not the platform with the loudest booth.
The idle-generator problem and the secondhand market
A physician can attend a sponsored course, purchase a generator and discover that patients do not automatically follow.
A device does not create referring-physician confidence, search visibility, patient awareness, reimbursement, self-pay demand, hospital privileges, documented outcomes or a sustainable case pipeline. Low volume creates a financial problem and a clinical problem: the physician may not progress through or maintain the learning curve.
Repurchase, trade-in, consignment or transfer support may preserve more value.
A general auction may not understand cooling systems, cables, software and consumable compatibility.
A second owner needs service, calibration, software and access to compatible electrodes.
Biomedical review, service history, serial numbers and local regulatory eligibility matter.
Does a secondhand market exist?
Yes, but it appears fragmented and substantially less liquid than the market for general ultrasound equipment. Capital components may be resold, but value depends on completeness of the system, OEM willingness to support a second owner, regulatory status and continued availability of proprietary consumables. Single-use applicators should never be informally reprocessed or resold after use.
Contract terms physicians should negotiate before purchase
Why resale value may be poor
What patients should ask before discussing the machine
Experience
How many thyroid ablations have you personally performed, and how many do you perform each month?
Ultrasound ownership
Do you personally perform the diagnostic examination and the procedural ultrasound?
Training
Who proctored your initial clinical cases, and how many supervised procedures did you complete?
Comparable disease
Have you treated lesions with my diagnosis, size, vascularity and anatomical location?
Safety
How do you identify and protect the recurrent laryngeal nerve, trachea, esophagus and vessels?
Outcomes
What are your rates of voice change, repeat treatment, incomplete margins and regrowth?
Alternatives
What treatment would you recommend if you did not own this device?
Referral integrity
Will you refer me elsewhere when another modality, surgery, surveillance or systemic treatment is more appropriate?
The conclusion that should guide the field
Thyroid ablation should not be marketed as a device-driven procedure. The decisive technology is high-level diagnostic and interventional ultrasound performed by an experienced physician.
Different technologies provide meaningful advantages for different lesions. RFA offers precision and the strongest overall clinical foundation. MWA may offer speed and efficiency for selected large or vascular nodules. Ethanol remains preferable for many cystic lesions. Laser remains an established regional alternative. Nanosecond pulsed-field ablation may eventually reduce some limitations of thermal treatment. Embolization may provide an option for selected massive or diffuse disease.
But no generator can compensate for weak ultrasound skills, poor patient selection, inadequate proctoring or low procedure volume.
The physician must know how to ablate. More importantly, the physician must know when not to ablate.
The best thyroid-ablation program is not defined by the machine it owns. It is defined by the quality of its imaging, the judgment of its physicians, the depth of its experience and its willingness to recommend the right treatment—even when that treatment uses a different device or occurs at another center.
Why I wrote this report
In 2013, I underwent a total thyroidectomy and neck dissection after being told that I needed to act quickly. The operation left me with a recurrent laryngeal nerve injury, vocal cord paralysis and permanent consequences.
I later came to question whether the urgency and extent of the operation were necessary—and whether active surveillance or less invasive treatment options should have been fully discussed before I agreed to irreversible surgery.
That experience made me an advocate for avoiding surgery when a safe, evidence-supported alternative can accomplish the clinical objective. It did not make me anti-surgery. Surgery remains necessary and potentially lifesaving for many patients.
This report is not an argument for using ablation in every patient. It is an argument for better diagnosis, better ultrasound, better physician training and treatment selected according to the disease—not according to the machine a clinic happens to own.
— Philip James
Medical Journalist and Victim of
Unnecessary Thyroid Surgery
Methodology, limitations and references
Editorial independence
This report was developed as an independent RFAMD assessment. Device manufacturers did not determine the rankings or conclusions. Before publication, RFAMD should disclose any current financial, referral, advertising or professional relationships relevant to the companies, clinicians or institutions discussed.
Method
The assessment prioritizes professional-society guidance, systematic reviews, peer-reviewed comparative studies, FDA records and securities filings. Manufacturer materials are used primarily to document product configurations, training activity and company claims. Because no audited worldwide registry reports procedure volume or installed base by manufacturer, the ranking should not be interpreted as a definitive global market-share table.
Limitations
- Device-specific comparative trials remain limited, and English-language publication visibility may underrepresent evidence published in Chinese or other languages.
- Commercial data are frequently self-reported or commissioned by manufacturers; the Chinese market comparison used here is based on 2022 data cited in Baird’s public filing, not an audited 2026 global registry.
- Regulatory indications differ by country and may change.
- Clinical outcomes are highly operator-dependent.
- Off-label use and institutional policy vary across jurisdictions.
- Studies using multiple MWA platforms strengthen the modality evidence but cannot be assigned wholly to one manufacturer.
Corrections policy
RFAMD welcomes documented corrections from physicians, researchers and manufacturers. Material corrections should be independently reviewed and recorded in a dated revision history. Contact: support@rfamd.com.
Selected references
- Sinclair CF, et al. General Principles for the Safe Performance, Training, and Adoption of Ablation Techniques for Benign Thyroid Nodules: An American Thyroid Association Statement. Thyroid. 2023.
- Papini E, et al. 2020 European Thyroid Association Clinical Practice Guideline for the Use of Image-Guided Ablation in Benign Thyroid Nodules.
- Radiofrequency Ablation for Recurrent Thyroid Cancers: 2025 Korean Society of Thyroid Radiology Guideline.
- Lim H, Cho SJ, Baek JH. Comparative efficacy and safety of radiofrequency ablation and microwave ablation in benign thyroid nodule treatment: systematic review and meta-analysis. European Radiology. 2025.
- U.S. FDA 510(k) Summary K252833: STARMED VIVA combo RF System. May 26, 2026.
- STARMED America: thyroid RFA system and U.S. indications.
- RF Medical THYBLATE system overview.
- Single-session radiofrequency ablation versus microwave ablation of predominantly solid benign thyroid nodules—a comparison after propensity score matching. European Radiology.
- U.S. FDA 510(k) Summary K232240: Baird / Betters Microwave Ablation System (BD-GT). 2023.
- Pulse Biosciences Form 10-Q for the quarter ended March 31, 2026.
- Pulse Biosciences company-reported benign thyroid nodule durability data. March 9, 2026.
- Thyroid Arterial Embolization for the Management of Benign and Malignant Thyroid Disease: A Systematic Review. Endocrine Practice. 2025.
- Thyroid Artery Embolization for Benign Thyroid Hyperplasia. Journal of Clinical Medicine. 2026.
- ECO Medical Technology: product and international activity information.
- Baird Medical: product and company information.
- Microwave versus Radiofrequency Ablation in Treating Predominantly Solid Benign Thyroid Nodules: A Randomized Controlled Trial. Radiology. 2024.
- Initial ablation ratio predicts recurrence of low-risk papillary thyroid microcarcinomas treated with microwave ablation: a five-year Canyon KY-2000 cohort.
- Canyon Medical ThyTip and MaxBlate product specifications.
- U.S. FDA 510(k) Summary K241827: Canyon Medical KY-2000A and KY-2100A Microwave Ablation Generators. 2024.
- Baird Medical 2025 Form 20-F: commissioned Chinese MWA market ranking and regulatory comparison of ECO, Vison, Baird and Canyon.
- Ultrasound-guided microwave ablation in the treatment of benign thyroid nodules in 435 patients, using the Canyon/Kangyou KY-2000 system.
- Evaluating microwave ablation for treating large benign thyroid nodules: a 205-patient Vison MTC-3C cohort. 2026.
- U.S. FDA 510(k) K223272: SurBlate Ablation System, designed by Vison Medical and manufactured by MIMA-Pro. 2023.
- Canyon Medical corporate milestones documenting the Kangyou/Canyon name history and Micro-Tech acquisition.
- Micro-Tech corporate overview identifying Canyon Medical as a majority-owned subsidiary and describing international expansion.
- Long-term outcome of microwave ablation for benign thyroid nodules using the ECO-100A1 platform.
- Terumo: NICE guidance and dedicated TATOpro thyroid antenna for percutaneous microwave ablation.
- Comparative study of cooled and uncooled single-treatment microwave ablation in thyroid nodules, including the HS AMICA system.
- Olympus CELON Power System: bipolar radiofrequency ablation procedure for benign thyroid nodules.
- Radiofrequency ablation of large solid benign thyroid nodules using the MedSphere S-500 and thyroid-specific electrodes.
Trademarks and visual presentation
Manufacturer names and product names are used for comparative editorial identification. RFAMD intentionally avoids decorative manufacturer logos in the principal rankings so the page does not imply sponsorship or endorsement.